The Supporters of Biozipcode initiative collaborates closely with two key partners: Biozipcode, Inc. and the Shiga University of Medical Science, Department of Regenerative Medicine.

Biozipcode, Inc. was established to apply and commercialize the research findings developed at the Shiga University of Medical Science, Department of Regenerative Medicine. The company is dedicated to pioneering new approaches to diabetes treatment and side-effect-free therapies, using cell-targeting technology.

Meanwhile, the Shiga University of Medical Science, Department of Regenerative Medicine plays a crucial role as an advanced medical research institution, driving deeper exploration into this field.

Both institutions collaborate by sharing scientific expertise and resources to advance the development of innovative treatments for diabetes.